YolTech Awarded Patent for Novel Lipid Nanoparticle Technology, Strengthening In-House Delivery Capabilities

YolTech Therapeutics recently received a patent grant (ZL202211695784.5) from the China National Intellectual Property Administration (CNIPA) for its proprietary lipid nanoparticle (LNP) delivery technology. This patent protects a new class of ionizable lipids with unique chemical structures, along with their synthesis methods, and extends to LNP formulations and drug products that utilize these lipids.

Nucleic acid-based therapies, such as mRNA, have garnered significant attention for their therapeutic potential. Efficient and targeted delivery systems are crucial for optimizing these treatments. YolTech’s newly patented lipid series demonstrates exceptional drug encapsulation efficiency, uniform particle size distribution, and stability, enhancing delivery to negatively charged therapeutic molecules. Notably, the synthesis process for these lipids is straightforward, cost-effective, and scalable, adding a valuable tool to YolTech’s LNP toolkit.

"As a leading gene editing company, YolTech remains committed to advancing proprietary innovations, from our editing platforms like YolCas™ and YolBE® to delivery systems such as YOL-LNPs®," said Dr. Emma Wang, Co-founder, CDO, and CTO of YolTech. "This newly granted patent exemplifies our strength in delivery technologies and paves the way for more efficient clinical translation of our innovations."

The company has built a robust patent portfolio covering its core technology platforms. Several key patents, including this lipid delivery breakthrough, have been authorized, addressing critical barriers in nucleic acid drug development and laying the foundation for future growth.

About YOL-LNPs® Delivery System

YolTech has developed a high-throughput LNP screening platform, generating a diverse library of ionizable lipids tailored for different therapeutic needs. YOL-LNPs® supports efficient nucleic acid delivery, designed with versatile core structures for a wide range of applications.

About YolTech Therapeutics

Founded in 2021, YolTech Therapeutics is an innovative biopharmaceutical company dedicated to developing in vivo gene editing therapies based on mRNA-LNP delivery. The company has pioneered the YolCas™ gene editor and the YolBE® base editor, alongside the proprietary YOL-LNPs® delivery system. With an R&D center and GMP manufacturing facility in Shanghai, YolTech continues to push the boundaries of gene editing and has initiated several landmark clinical trials, including treatments for ATTR, familial hypercholesterolemia (FH), and primary hyperoxaluria (PH1).